MobileODT is pleased to announce it has successfully completed its second round of institutional financing. The announcement comes shortly before the launch of its AI-based cervical cancer screening test, VisualPap.
OrbiMed Israel Advisors led the round, with Tara Health, Laerdal Global, and Sanford Biosciences joining as new investors.
This new round of financing will enable MobileODT to launch its VisualPap test in the coming months, starting in South Korea. VisualPap is a point-of-care test for automated visual evaluation (AVE) of the cervix, using artificial intelligence (AI) to detect the presence of cervical dysplasia (pre-cancer) using digital images of the cervix. VisualPap can only be conducted from MobileODT’s EVA System digital colposcope, strengthening MobileODT’s point-of-care cervical cancer screening solution.
“We are excited to close this funding round just prior to the launch of VisualPap. It demonstrates the recognition of VisualPap’s potential to revolutionize cervical cancer screening,” says MobileODT CEO, Ariel Beery. “We are grateful to our partners around the world, both clinical and commercial, for their faith and support in bringing this life-saving technology to practical application.”
